Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL44064 | 1.00 | TSHR (0.40) | TSHRNAPRTTDP1CYP2A6CYP11B2 | |
| Pyrimidine SCHEMBL5662611 | 1.00 | — | — | |
| Pyrimidine SCHEMBL1723992 | 1.00 | TSHR (0.40) | TSHRNAPRTTDP1CYP2A6CYP11B2 | |
| Pyrimidine SCHEMBL1846 | 0.87 | — | — | |
| Pyrimidine SCHEMBL19437633 | 0.87 | TSHR (0.50) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL10646 | 0.87 | TSHR (0.50) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL9545353 | 0.82 | — | — | |
| Pyrimidine SCHEMBL22346941 | 0.82 | — | — | |
| Pyrimidine SCHEMBL21315895 | 0.82 | TSHR (0.46) | TSHRNAPRTTDP1CYP2A6 | |
| Pyrimidine SCHEMBL383109 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307839-A1 | Enzyme Replacement Therapy for Melanoma | CORREIA PEDRO BRITO (PT) | 2019-10-10 | — | — | US | disclosed |
| US-20030223982-A1 | Use of DNA repair enzymes as MMP 1 inhibitors | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030223982-A1 | Use of DNA repair enzymes as MMP 1 inhibitors | MMP1, DNASE1, MMP9 | TSHR 4607/4885NAPRT 840/4885TDP1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.